A wave of fresh research is reshaping how doctors treat acute lymphoblastic leukemia (ALL). First, a Chinese team led by Prof. Zhou Hongsheng and Prof. Wang Liang has built the inaugural metabolic‑feature classification for B‑ALL, sorting patients into three sub‑types that differ in their energy‑use patterns, outlook, and drug vulnerabilities. At the same time, scientists are decoding why leukemia cells hide in the brain and spinal cord, pinpointing the signaling and metabolic tricks that let them survive and resist therapy. At MD Anderson, new 2025 data show how cutting‑edge drugs and precision strategies can be woven together for adult ALL, while a nationwide Swedish cohort pinpoints the risk factors that drive central‑nervous‑system relapse. In China, the largest real‑world study to date confirms that measuring relapse at day 12 or day 24 after treatment sharpens prognosis for pediatric B‑ALL. For Philadelphia‑chromosome‑positive ALL, British researchers propose a risk‑adaptive framework to guide post‑transplant TKI maintenance. Highlights from EHA 2026 reveal why high‑risk patients still show varied outcomes and map the full genomic landscape of adult ALL for the first time. Finally, a US consensus panel offers practical tips to overcome barriers to safe asparaginase use. Together, these advances explain why immunotherapy remains a vital partner to chemotherapy in the fight against ALL.
Read more